$PSNL

Hall Christopher M sold $219K of PSNL

Hall Christopher M (Chief Executive Officer) sold 19,909 shares of Personalis, Inc. (PSNL) at $11.02 ($0.22M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hall Christopher M
Published May 30, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider confidence, but the 10b5-1 designation typically lowers interpretive weight.

02

Market read

A disclosed CEO sale may cause minor sentiment drift, but it is unlikely to drive a sustained repricing without accompanying fundamentals.

03

What to watch

The filing does not reveal why the shares were sold or whether other insiders/funds acted; it also provides no new operational/clinical updates.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed May 29 for a May 28 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Personalis, Inc. (PSNL).

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

Personalis CEO Christopher M. Hall sold 19,909 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited/short-lived price impact; any move would be sentiment-driven rather than news-driven.

Evidence & confidence

The filing is a routine insider transaction with stated 10b5-1 pre-arrangement, reducing the signal of new negative information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide read-through stated.

None indicated.

None indicated.

Counterpoint

Because the sale was pre-arranged under a Rule 10b5-1 plan, it may reflect scheduled liquidity needs rather than a change in outlook.

Key entities

  • Personalis, Inc.

    Subject of the SEC Form 4 insider sale by its CEO.

  • Christopher M. Hall

    CEO and director who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.